Read More

IMAX Corporation Responds To Results Of Shareholder Vote On IMAX China Privatization Transaction; Despite 70% Of Shareholders Voting “For”, Proposed Transaction Does Not Meet The Necessary Threshold For Approval

Despite 70% of Shareholders Voting "FOR", Proposed Transaction Does Not Meet the Necessary Threshold for ApprovalNEW YORK, Oct. 10, 2023 /PRNewswire/ -- IMAX Corporation (NYSE:IMAX) today confirmed that the Company's

IMAX

Read More

Athersys Reports Interim Analysis Results Of MASTERS-2 Clinical Study With MultiStem In Ischemic Stroke, Signs Memorandum Of Understanding For Global ARDS License With Healios; Includes $1.5M To $4.5M Near Term Payments Plus Up To $150M In Milestones

The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestonesAthersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care

ATHX